Malignant Pleural Mesothelioma: Present Status and Future Directions

Analysis of Therapies for Malignant Pleural Mesothelioma: Words that Count, Numbers that Speak

Author(s): Francesca Fiorentino and Tom Treasure

Pp: 515-520 (6)

DOI: 10.2174/9781681081946116010039

* (Excluding Mailing and Handling)

Abstract

Evaluating the benefit of therapies for malignant mesothelioma is a quite difficult task. The difficulty lies in identifying patients who might have benefited from a given treatment but knowingly did not receive it. Unless these 'suitable' patients have been identified in advance of any treatment and the process of allocation to one treatment or another is without bias. This is best achieved by randomization and in our view, for relatively small trials with heterogeneous patients, that is best done with the additional step of minimization.


Keywords: Observational data, outcome, sample size, selection bias, statistical analysis.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy